Nothing random about medical animator’s growth

Neuron Animation
A neuron animation dramatically illustrates the level of scientific imagery that Random42 generates

With an in-house team of PhD scientists, Random42 has won numerous accolades

Queen’s Award for International Trade

By Graham Lironi

Click to access article as a .pdf

It may well be called Random42, but there’s nothing haphazard about this medical animator’s recent dramatic growth. This has led to it winning a Queen’s Award for Inter-National Trade for Outstanding Continuous Growth in overseas sales to add to an already top-heavy awards cabinet groaning under the weight of 150 other accolades.

Founded in 1992 by Hugo Plaice, when its focus was primarily on creating animations for the pharmaceutical industry – it has worked with 23 of the top 25 pharma companies – this London-based studio has since diversified into a variety of other digital services, including virtual reality, interactive apps, interactive touchscreens, augmented reality and booth installations.

One of the pioneers of medical animation, being one of the first to develop animated sequences used to demonstrate the mechanism of action (MOA) of a drug or disease area, Random42 consists of scientists, art-sits, animators and programmers who collaborate to produce some of the most impactful and medically accurate scientific imagery, stories and interactive experience.

Its in-house team of PhD scientists leads every project, so that clients can relay complex information that can be translated

Ben Ramsbottom CEO of Random42
Ben Ramsbottom, CEO of Random42 has increasingly targeted the US
marketplace

seamlessly into a deliverable that can elevate a product or disease area to a new level. When Ben Ramsbottom, CEO, joined eight years ago, the firm employed five staff. Today that number has mushroomed to 60.

Over the past six years, the offering it can provide has expanded substantially too, with the advent of tablets, large touchscreens, virtual reality headsets and fast broadband streaming meaning that the company can elevate its visual storytelling to a new level.

“We believe that our experience and knowledge in this space is unparalleled, gaining a huge level of experience across almost all therapeutic areas through the digital assets we have created for over 550 global pharmaceutical products,” said Mr Ramsbottom.

“We have also worked extensively in the areas of consumer health, medical devices and diagnostics tests, as well as collaborating with the film industry to develop various documentaries that can be seen in IMAX theatres globally.

“And with only 10-15% of its turnover emanating from the UK, some 70% is generated from US-based clients. “It is our success in the US that has won us the Queen’s Award,” noted Mr Ramsbottom.

“We operate in a growing market and have taken advantage of that to expand substantially the level of business we do in the US.

“We are positioned to grow rapidly over the next five years and beyond, being a world-leader in science education, both from a pharma perspective but also the broader research community but also university students and beyond.

“We see a lot of value-add that we can provide in those areas; not just classic drug launches, but real disease education. Great science coupled with the amazing work coming from our creative team, we see as a real differ-initiator in the market.”

Over the course of its last two financial years, Random42 has grown its turnover by 35% and is forecasting an average annual growth rate of more than 20% over the next three to five years. “That is our target for the company – and there are various market reports to suggest that the market within which we operate will continue to expand at that rate,” said Mr Ramsbottom.

“Yet while much of our growth will be organic, we have firm plans in place to invest in the business to ensure that we maintain a stranglehold over this expanding global market”.

Confirmation, if any were needed, that there is nothing haphazard about this medical animator’s success.